Tag Archives: cardiovascular risk
March 2010 Br J Cardiol 2010;17:81-5
10 Steps before you refer for Chronic Kidney disease
Kathryn E Griffith, Philip A Kalra
(more…)
May 2009 Br J Cardiol 2009;16:113–15
Cardiovascular risk in rheumatoid arthritis
Ian Kelt, Neal Uren
Atherosclerosis and inflammation It is not clearly understood why patients with rheumatoid arthritis should suffer accelerated atherosclerosis. Traditional modifiable risk factors alone are insufficient to explain the excess cardiovascular risk.3-5 Part of the answer is that rheumatoid arthritis causes chronic systemic inflammation, which may accelerate the atherosclerotic process. Atherosclerosis is essentially an inflammatory disease, with levels of different biomarkers of inflammation such as C-reactive protein (CRP), interleukin-6, and N-terminal prohormone B-type natriuretic peptide (NTproBNP) correlating closely with subsequent cardiac
July 2008 Br J Cardiol 2008;15:210-14
Clinical experience with prolonged-release nicotinic acid in statin-treated patients managed in Ireland
Michael O’Reilly, Ulrike Hostalek, John Kastelein
Introduction Cardiovascular events remain the leading cause of morbidity and mortality in developed countries, and the treatment of dyslipidaemia is central to the overall management of cardiovascular risk.1,2Although correction of hypercholesterolaemia remains the principal target for correction of the lipid profile, dyslipidaemia is heterogeneous in presentation, with many patients presenting with low high-density lipoprotein-cholesterol (HDL-C) in addition to elevated concentrations of ApoB-containing lipoproteins. A survey carried out in 11 European countries identified low HDL-C (<1.03 mmol/L in men and <1.29 mmol/L in women) in ab
March 2008 Br J Cardiol 2008;15:65-6
Rosiglitazone and pioglitazone – where do we go from here?
Sarah Jarvis
The struggle to meet targets GPs are struggling to meet these targets, with only 56–59% of patients achieving HbA1c <7.5% in at least 50% of patients in 2004/5, and 59–62% of patients in 2005/6.6 While metformin has an excellent safety and efficacy record, and continues to be standard first-line therapy for all patients who can tolerate it, UKPDS has shown us that for most patients, multiple hypoglycaemic agents are necessary. Sulphonylureas are also well tried and tested, and relatively cheap, but carry the risk of weight gain and hypoglycaemia, especially with longer-acting versions such as chlorpropamide and glibenclamide. In additi
March 2007 Br J Cardiol 2007;14:69-70
Homocysteine – is it the end of the line?
Patrick O’Callaghan
No content available
November 2006 Br J Cardiol 2006;13:411-8
Cost-effectiveness of adding prolonged-release nicotinic acid in statin-treated patients who achieve LDL cholesterol goals but remain at risk due to low HDL cholesterol: a UK-based economic evaluation
BJCardio editorial team
No content available
September 2006 Br J Cardiol 2006;13:347-50
Should cardiologists be interested in albuminuria?
Clive Weston, Achanthodi Vasudev, Daniel Obaid, Saatehi Bandhopadhay, Jiten Vora
No content available
March 2005 Br J Cardiol (Acute Interv Cardiol) 2006;13:AIC 14–AIC 18
Risk of death, MI and patterns of care delivered in non-ST elevation ACS patients with intermediate elevations in cardiac troponin T: a UK DGH experience
Kausik Ray, James Bolton, Alice Veitch, Paul Sheridan, Michael Gillett, Ahmed Al Rifai, Ramasamy ManivArmane, Alan Brennan, Gillian Payne, Wazir Baig
No content available
November 2003 Br J Cardiol 2003;10:472-7
Computer-enhanced assessment of cardiovascular risk
Peter Tyerman, Gill V Tyerman, Trefor Roscoe, Mike Campbell, Jenny Freemen
No content available
July 2003 Br J Cardiol 2003;10:310-4
The need for 24-hour blood pressure control
Mike Mead
No content available
For healthcare professionals only
